Us3 Kinase Encoded by Herpes Simplex Virus 1 Mediates Downregulation of Cell Surface Major Histocompatibility Complex Class I and Evasion of CD8+ T Cells

Takahiko Imai1,2,3, Naoto Koyanagi1,2, Ryo Ogawa1,2, Keiko Shindo1,2, Tadahiro Suenaga3,7, Ayuko Sato4, Jun Arii1,2, Akihisa Kato1,2, Hiroshi Kiyono4,5, Hisashi Arase6,7, Yasushi Kawaguchi1,2*

1 Division of Molecular Virology, Department of Microbiology and Immunology, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan, 2 Division of Viral Infection, Department of Infectious Disease Control, International Research Center for Infectious Diseases, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan, 3 Nippon Institute for Biological Science, Ome, Tokyo, Japan, 4 Division of Mucosal Immunology, Department of Microbiology and Immunology, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan, 5 Core Research for Evolutional Science and Technology, Japan Science and Technology Agency, Saitama, Japan, 6 Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan, 7 World Premier International Research Center Immunology Frontier Research Center, Osaka University, Suita, Osaka, Japan

Abstract

Detection and elimination of virus-infected cells by CD8+ cytotoxic T lymphocytes (CTLs) depends on recognition of virus-derived peptides presented by major histocompatibility complex class I (MHC-I) molecules on the surface of infected cells. In the present study, we showed that inactivation of the activity of viral kinase Us3 encoded by herpes simplex virus 1 (HSV-1), the etiologic agent of several human diseases and a member of the *Alphaherpesvirinae*, significantly increased cell surface expression of MHC-I, thereby augmenting CTL recognition of infected cells in vitro. Overexpression of Us3 by itself had no effect on cell surface expression of MHC-I and Us3 was not able to phosphorylate MHC-I in vitro, suggesting that Us3 indirectly downregulated cell surface expression of MHC-I in infected cells. We also showed that inactivation of Us3 kinase activity induced significantly more HSV-1-specific CD8+ T cells in mice. Interestingly, depletion of CD8+ T cells in mice significantly increased replication of a recombinant virus encoding a kinase-dead mutant of Us3, but had no effect on replication of a recombinant virus in which the kinase-dead mutation was repaired. These results indicated that Us3 kinase activity is required for efficient downregulation of cell surface expression of MHC-I and mediates evasion of HSV-1-specific CD8+ T cells. Our results also raised the possibility that evasion of HSV-1-specific CD8+ T cells by HSV-1 Us3-mediated inhibition of MHC-I antigen presentation might in part contribute to viral replication in vivo.

Introduction

Herpes simplex virus-1 (HSV-1) is the member of the *Alphaherpesvirinae*, the neurotropic subfamily of herpesviruses [1]. Like other herpesviruses, HSV-1 causes a life-long infection cycling between lytic and latent phases in the natural human host [1]. This HSV-1 life-cycle repeatedly primes the host immune system, thereby increasing the potential for the host to eradicate the virus. To overcome this situation, HSV-1 has had to evolve mechanisms to evade immune detection and clearance [2,3].

CD8+ cytotoxic T lymphocytes (CTLs) play an important role in the clearance of herpesvirus-infected cells [2,3]. CD8+ CTLs recognize viral antigens presented as peptides bound to major histocompatibility complex class I (MHC-I) molecules, which are assembled in the endoplasmic reticulum (ER), at the surface of infected cells [4]. Therefore, the MHC-I antigen presentation pathway seems to be a prime target for
herpesviruses to attack to evade the host immune system. In fact, numerous reports have shown that various herpesvirus proteins have evolved to inhibit MHC-I antigen presentation in vitro by a variety of mechanisms [2,3]. However, the data that these in vitro mechanisms affect viral replication and pathogenesis in vivo is limited to some non-human, animal herpesviruses in the *Betaherpesvirinae* or *Gammaherpesvirinae* [5–7].

HSV has been reported to encode two viral proteins, ICP47 and virion host shutoff protein (vhs), that inhibit antigen presentation on MHC-I to CD8+ CTLs in vitro [8,9]. ICP47 binds to the transporter associated with antigen processing (TAP), which translocates antigen peptides derived from proteosomal degradation of viral proteins into the endoplasmic reticulum (ER) [4], where the antigen peptides are loaded onto newly synthesized MHC-I [4]. ICP47 acts as a high-affinity competitor for peptide binding to TAP, thereby inhibiting MHC-I antigen presentation on the surface of HSV-infected cells [10,11]. While HSV ICP47 efficiently inhibits MHC-I antigen presentation in human cells [8], inhibition of antigen presentation in murine cells is only marginally effective, due to about a 100-fold decrease in ICP47 binding to murine TAP compared to human TAP [11,12]. Consistent with these data, ICP47 protects HSV-infected human fibroblasts from destruction by CD8+ CTLs, while mouse fibroblasts are not protected [13]. These ICP47 properties make it difficult to address the importance of ICP47-mediated inhibition of MHC-I presentation of HSV antigens in murine models, which have been extensively used to study the pathogenesis and immunological control of HSV infection. In contrast, despite the limited ability of ICP47 to inhibit mouse TAP, a role for ICP47 in evasion of CD8+ T cell-mediated immunity in mice was suggested by a study showing that CD8+ CTLs were able to protect mice from an HSV mutant lacking ICP47 but not from wild-type virus [14]. Thus, the mechanism by which ICP47 acts in evasion of CD8+ CTLs in mice remains uncertain at present. vhs, another HSV protein involved in evasion of CD8+ CTLs by inhibition of MHC-I antigen presentation, is an mRNA-specific RNase that triggers rapid shutoff of host cell protein synthesis [15] and inhibits synthesis of MHC-I in HSV-infected cells [9]. HSV-2 vhs has been reported to help infected cells become resistant to lysis by CD8+ CTLs in vitro [9]. However, vhs appears not to play a role in evasion of CD8+ CTLs in vivo, based on the observation that a vhs-null mutation in HSV-2 attenuated viral replication and pathogenesis in SCID mice to levels similar to those in normal mice [16].

In some alphaherpesviruses [e.g., bovine herpesvirus 1 (BHV-1), pseudorabies virus (PRV), equine herpesvirus 1 and 4 (EHV-1 and EHV-4) and Marek’s disease virus], UL49.5 homologs have been reported to inhibit MHC-I antigen presentation by affecting the function of TAP [17–19]. However, in other alphaherpesviruses [e.g., HSV and varicella zoster virus (VZV)], UL49.5 homologs are not involved in inhibition of MHC-I antigen presentation, suggesting that the role of conserved alphaherpesvirus gene products in MHC-I antigen presentation may vary. VZV ORF66, a serine/threonine protein kinase, has also been reported to down-regulate cell surface expression of MHC-I through the cis-medial-Golgi complex [20]. In addition, PRV Us3, a homolog of VZV ORF66, was shown to be required, but not sufficient, for downregulation of cell surface expression of MHC-I [21]. Moreover, HSV-1 Us3 has been reported to collaborate with viral envelope glycoprotein B (gB) to downregulate cell surface expression of MHC-I-like antigen-presenting molecule CD1d to potently inhibit its recognition by CD1d-restricted natural killer T cells [22]. UL56 homologs in EHV-1 and EHV-4 were also recently reported to downregulate cell surface expression of MHC-I [23,24]. However, it remains to be determined whether UL49.5, ORF66, Us3 and UL56 proteins protect virus-infected cells from destruction by CD8+ CTLs in vitro and whether their potential immune evasion functions contribute to viral replication in vivo.

In the present study, we showed that the activity of HSV-1 Us3 was required for efficient inhibition of MHC-I antigen presentation to prevent CTL recognition of infected cells in vitro and for downregulation of induction of HSV-1-specific CD8+ T cells in mice. Us3 appeared to indirectly downregulate MHC-I since Us3 was not sufficient for MHC-I downregulation and Us3 was not able to phosphorylate MHC-I in vitro. Depletion of CD8+ T cells in mice significantly increased replication of a recombinant virus encoding a kinase-dead mutant of Us3, but had no effect on replication of a recombinant virus in which the kinase-dead mutation was repaired. Our results raised the possibility that inhibition of MHC-I antigen presentation mediated by HSV-1 Us3 kinase activity might in part contribute to viral replication in vivo.

**Materials and Methods**

**Cells and viruses**

Vero, 293T and B6MEFs, an immortalized mouse embryonic fibroblast (MEF) cell line derived from wild-type C57BL/6J mice, were described previously [25,26]. MRC-5 cells, human normal embryonic lung fibroblasts, were obtained from the Riken BioResource Center. MHC-I-MEFs, an immortalized MEF cell line derived from C57BL/6J mice lacking the gene encoding MHC-I (a gift from Dr. A.B. Hill), and HSV-2.3.2E2 cells, a lacZ-inducible CD8+ T cell hybridoma that recognizes HSV-1 gB gB58–60 (a gift from Dr. F.R. Carbone), are described elsewhere [27]. HSV-1 wild-type strain HSV-1(F), recombinant virus YK511 encoding an enzymatically inactive Us3 mutant in which lysine at Us3 residue 220 was replaced with methionine (Us3-K220M), recombinant virus YK513 in which the Us3 K220M mutation in YK511 was repaired (Us3-repair) and recombinant virus YK476 (ΔUL41) in which the UL41 gene was disrupted by the insertion of a foreign gene cassette carrying a stop codon just downstream of the UL41 start codon, an I-SceI site, a kanamycin resistance gene, and 60 bp of a sequence upstream of the second codon of the UL41 gene (Fig. 1) were described previously [28]. Recombinant virus YK477 (ΔUL41-repair) in which the foreign gene cassette inserted into the UL41 locus of YK477 was excised (Fig. 1) was generated as described previously [28] except using *E. coli* containing the YK477 genome. Recombinant virus YK478 encoding UL41 with an aspartic acid substitution for asparagine at amino acid 213 (UL41D213N) (Fig. 1) was generated as described previously.
except using primers 5'-CCTCTATCACACCAACACGGTCGCGTACGTGTACACCACGACACTGACCTCCTGTTGATGAGGATGACGACGATAAGTGGG-3' and 5'-TCCAACAATATCGCAGCCCATCAACAGGAGGTCAGTGTCCGTGGTGTACACGTACGCGACAACCAATTAACCAATTCTGATTAG-3'. Recombinant virus YK479, in which the UL41D213N mutation in YK478 (Fig. 1) was repaired, was generated as described previously [29] except with the primers 5'-CCTCTATCACACCAACACGGTCGCGTACGTGTACACCACGACACTGACCTCCTGTTGATGAGGATGACGACGATAAGTGGG-3' and 5'-TCCAACAATATCGCAGCCCATCAACAGGAGGTCAGTGTCCGTGGTGTACACGTACGCGACAACCAATTAACCAATTCTGATTAG-3'. Recombinant virus YK591 with a 100 bp deletion (42 bp upstream to 55 bp downstream of the start codon) in ICP47 (ΔICP47) (Fig. 1) was constructed by the two-step Red-mediated mutagenesis procedure as described previously [29], except using primers 5'-TTGCGTGGACCGCTTCCTGCTCGTCGGGGCGACCGGCGGCGGACGTACGCCGACGTACGCAGGATGACGACGATAAGTAGGG-3' and 5'-CCCCTTTTATTGATCTCATCGCGTACGTCGGCGTACGTCCGCCGCGTCGCCGCCGACGACAACAACTAACTAACTGATTAG-3'. This deletion in ICP47 was reported to eliminate ICP47 expression and have no effect on expression of the neighboring Us11 gene [14].

Analysis of cell surface expression of MHC-I

Cell surface and total expression of human and mouse MHC-I in infected cells was determined as described previously [30,31], except that FITC-conjugated anti-human-HLA-ABC (G46-2.6; Becton Dickinson), anti-mouse-H-2Kb (AF6-88.5; BioLegend) and anti-mouse-H-2Db (28-14-8; eBioscience) antibodies were used. Cell surface expression of human MHC-I in 293T cells co-transfected with pEGFP-C1 (clontech) in combination with pFLAG-CMV-2 or pFLAG-Us3 was analyzed as described above, except that EGFP-positive cells were gated, and anti-human HLA-ABC antibody (G46-2.6 Becton Dickinson) and Alexa Fluor 680 Goat Anti-mouse IgG F(ab')2 fragment (Invitrogen) were used. pFLAG-Us3 was constructed by cloning the entire coding sequences of Us3 and Us3 carrying K220M mutation amplified from pBS-Us3 [32] into pFlag-CMV-2 (Sigma). 293T cells transfected with pFLAG-Us3 expressed Us3 efficiently (data not shown).

In vitro kinase assay. pMAL-gB-P2 and pMAL-gB-P2-T887A were described previously [31]. To generate a fusion protein of maltose binding protein (MBP) and part of MHC-I, pMAL-MHC-I was constructed by amplifying the domain encoding MHC-I codons 211-365 by PCR from a HeLa cDNA library (BioChain) and cloning the DNA fragments into pMAL-c (New England BioLabs) in frame with MBP. To generate a fusion protein of MBP fused to part of MHC-I in which the serines at MHC-I residues 336 and 337, which are potential PKA phosphorylation sites, were replaced with alanines (MHC-I-SS336/337AA), pMAL-MHC-I was mutated to generate pMAL-MHC-I-SS336/337AA as described previously [31]. MBP fusion proteins MBP-gB, MBP-gB-T887A, MBP-MHC-I and MBP-MHC-I-SS336/337AA were expressed in E. coli that had been transformed with pMAL-gB-P2, pMAL-gB-P2-T887A, pMAL-MHC-I and pMAL-MHC-I-SS336/337AA, respectively, and purified as described previously [31]. The purified MBP fusion proteins were captured on amylose beads (New England BioLabs) and used as substrates for in vitro kinase assays, as described previously [31], with glutathione S-transferase (GST)-Us3 purified as described previously [32] and protein kinase A (PKA) purchased from New England BioLabs.

Detection of antigen presentation in infected cells

B6MEF and MHC-I−/−MEF cells were grown in 24-well plates and infected with each of the indicated viruses at an MOI of 1. At 12 h post-infection, 5 x 10^4 HSV-2.3.2E2 cells were added to each well and incubation was continued for an additional 12 h.
LacZ expression was then determined as described previously [5].

Quantitative RT-PCR

Total RNA was isolated from infected cells with a High Pure RNA Isolation Kit (Roche) and cDNA was synthesized from the isolated RNA with a Transcriptor First Strand cDNA Synthesis Kit (Roche) according to the manufacturer’s instructions. The amount of cDNA of specific genes was quantitated using the Universal ProbeLibrary (Roche) with TaqMan Master (Roche) according to the manufacturer’s instructions. Gene-specific primers and universal probes were designed using ProbeFinder software (Roche). The primer and probe sequences for human β-actin were 5’-CCACCCGCAGAATGTA-3’, 5’-CCAGAGCTACAGGGATAG-3’ and Universal ProbeLibrary probe 64; for mouse β-actin were 5’-GGAGGGTTGAGGTCTA-3’, 5’-GTGTCACATTATGGCTCTCA-3’ and Universal ProbeLibrary probe 71 and for 18S rRNA were 5’-GCAATTATTCCCCATGAACG-3’, 5’-GGGACTTAATCAACGCAAGC-3’ and ProbeLibrary Probe 48. The amount of β-actin expression was normalized to the amount of 18S RNA expression. The relative amount of each gene expression was calculated using the comparative CT (2-ΔΔCT) method [33].

Preparation of NK cells and analysis of γ-IFN production

NK cells were purified and cultured as described previously [34]. For analysis of γ-IFN production, 2x10⁵ NK cells were co-cultured with 2 x 10⁵ B6MEFs infected with each of the indicated viruses for 24 h. Enzyme-linked immunosorbent assays (ELISA) were performed using Mouse IFN gamma ELISA Ready-SET-Go! (eBioscience) according to the manufacturer’s instructions.

Animal studies

Three or two six-week-old female C57BL/6J mice were mock-infected or infected with 1 x 10⁶ PFU of the indicated virus/footpad. At 4 d post infection, spleen and popliteal lymph node white blood cells from infected mice sacriﬁced by cervical dislocation were stained with MHC-I tetramer for the HSV-1 gB epitope (gBS39-50) (MBL). Cells were then stained with FITC-conjugated anti-CD8α (eBioH35-17.2; eBioscience) and APC-ant CD3ε (145-2C11; eBioscience) antibodies as described previously [30] and analyzed with a FACSCalibur with Cell Quest software (Becton Dickinson). The results were based on 9 experiments with HSV-1(F), YK511 (Us3K220M) and YK513 (Us3k220M-repair) and 5 experiments with YK591 (ΔICP47), and expressed as the percentage of gB-specific MHC-I tetramer positive cells that stained positive for CD8α. For depletion of CD8⁺ T or NK cells in mice, 200 µg anti-CD8α (53.6.72 obtained from ATCC) or anti-NK1.1.1 (PK136 obtained from ATCC) antibody, respectively, was administered to 6-week-old female C57BL/6J mice by intraperitoneal injection 2 d before HSV-1 infection. Administration of these antibodies into mice routinely resulted in >95% depletion of CD8⁺ and NK1.1⁺ cells in lymph node and spleen (Fig. S1). The depleted condition was maintained by repeated injections of monoclonal antibody at 3 d intervals. Three mice depleted of CD8⁺ T or NK cells were infected with 1 x 10⁶ PFU YK511 (Us3-K220M) or YK513 (Us3-Repair)/footpad. At 1 and 4 d post-infection, mice were sacriﬁced by cervical dislocation and footpads were harvested, homogenized and sonicated. Viral titers in the footpads were determined by standard plaque assays on Vero cells. The results were based on two experiments. All animal experiments were carried out in accordance with the Guidelines for Proper Conduct of Animal Experiments, Science Council of Japan. The protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the Institute of Medical Science, The University of Tokyo (IACUC protocol approval number: 19-26).

Results

Effect of HSV-1 Us3 kinase activity on cell surface expression of MHC-I in infected human and murine cells

We previously reported that HSV-1 Us3 directly phosphorylates HSV-1 envelope glycoprotein B (gB) and down-regulates its cell surface expression in infected cells by promoting gB endocytosis [30,31]. Moreover, Us3 homologs in VZV and PRV down-regulate cell surface expression of MHC-I in infected cells, as described above [20] and reported by Deruelle [21]. These observations prompted us to examine whether MHC-I is also a target of HSV-1 Us3 in the regulation of its cell surface expression in infected cells. As shown in Figure 2A and B, wild-type HSV-1(F) infection of MRC-5 cells, human primary lung ﬁbroblasts, resulted in signiﬁcant down-regulation of MHC-I cell surface expression as reported previously [35]. In contrast, MHC-I cell surface expression increased signiﬁcantly in MRC-5 cells infected with YK511 (Us3K220M), a Us3 kinase-dead mutant virus, compared to MRC-5 cells infected with wild-type HSV-1(F) or YK513 (Us3-repair), a recombinant virus in which the kinase-dead mutation in Us3 was repaired. However, the total accumulation of MHC-I protein in YK511-infected cells was similar to that in cells infected with HSV-1(F) or YK513 (Us3-repair) as described below (Fig. S5B). Furthermore, cell surface expression of gD and gH in MRC-5 cells infected with YK511 (Us3K220M) was similar to that in MRC-5 cells infected with wild-type HSV-1(F) (Fig. 2C and D). Similar results were also obtained for cell surface expression of H-2Kb and H-2Db in B6MEFs, a mouse cell line (Fig. 3 and Fig. S6B and D). These results indicated that Us3 kinase activity was required for efficient down-regulation of MHC-I cell surface expression in both human and murine cells infected with HSV-1.

Effect of HSV-1 Us3 in the absence of any other viral proteins on cell surface expression of MHC-I and on phosphorylation of MHC-I in vitro

To investigate whether Us3 by itself directly acts on MHC-1 or indirectly via other Us3-dependent viral and/or cellular protein(s), we performed two series of experiments. In the first series of experiments, 293T cells were transfected with a...
Figure 2. Effect of Us3 kinase activity on cell surface expression of MHC-I, gD and gH in HSV-1-infected MRC-5 cells. (A) Cell surface expression of MHC-I in human MRC-5 cells mock-infected (filled purple histogram) or infected with wild-type HSV-1(F) (green line), YK511 (Us3-K220M) (pink line) or YK513 (Us3-repair) (blue line) at an MOI of 3 for 18 h and analyzed by flow cytometry. The data are representative of five independent experiments. (B) Quantitation of cell surface expression of MHC-I in infected MRC-5 cells. The relative mean fluorescence intensity (MFI) for MHC-I expression on the surface of cells infected with the indicated virus is shown as relative to that of mock-infected cells. Each data point is the mean ± standard error of five independent experiments. (C and D) Surface expression of gD (C) and gH (D) in MRC-5 cells infected with HSV-1(F), YK511 (Us3-K220M) or YK513 (Us3-repair) at an MOI of 3 for 18 h and analyzed and quantitated as described in Figure 2B. Each data point is the mean ± standard error of triplicate samples, and is representative of three independent experiments.

doi: 10.1371/journal.pone.0072050.g002

Figure 3. Effect of Us3 kinase activity on cell surface expression of MHC-I (H-2Kb and H-2Db), gD and gH in HSV-1-infected MEFs from C57BL/6J mice (B6MEFs). (A and B) Surface expression of H-2Kb (A) and H-2Db (B) in B6MEFs mock-infected or infected with HSV-1(F), YK511 (Us3-K220M) or YK513 (Us3-repair) at an MOI of 3 for 18 h and analyzed and quantitated as described in Figure 2B. Each data point is the mean ± standard error of three independent experiments. (C and D) Surface expression of gD (C) and gH (D) in B6MEFs infected with HSV-1(F), YK511 (Us3-K220M) or YK513 (Us3-repair) at an MOI of 3 for 18 h and analyzed and quantitated as described in Figure 2B. Each data point is the mean ± standard error of triplicate samples, and is representative of three independent experiments.

doi: 10.1371/journal.pone.0072050.g003

Plasmid expressing wild-type Us3 or an empty expression plasmid and cell surface MHC-I was then analyzed. As shown in Figure S2A, expression of Us3 had little effect on cell surface expression of MHC-I. In the second series of experiments, we generated and purified a chimeric protein consisting MBP fused to peptides encoded by MHC-I codons 211 to 365 (MBP-MHC-I) which included the entire cytoplasmic domain of MHC-
I. We also generated a mutated version of MBP-MHC-I (MBP-MHC-I-SS336/337AA) in which alanines were substituted for serines at positions 336 and 337, which has been reported to be phosphorylated by protein kinase A (PKA) [36]. These MBP fusion proteins were used as substrates for in vitro kinase assays with purified GST-Us3 and PKA. MBP-gB and a mutated version of MBP-gB (MBP-gB-T887A) in which alanine was substituted for serine at position 887 which were shown to phosphorylated by GST-Us3 [31] were also used in these assays. As shown in Figure S2B, GST-Us3 did not phosphorylated MBP-MHC-I. In contrast, GST-Us3 and PKA phosphorylated MBP-gB and MBP-MHC-I, respectively, but not MBP-gB-T887A and MBP-MHC-I-SS336/337AA as reported previously [31,36] (Fig. S2B). Taken together, these results suggested that Us3 indirectly down-regulated cell surface expression of MHC-I.

Effect of HSV-1 Us3 kinase activity on HSV-1-specific antigen presentation in infected cells

Inhibition of HSV-1-specific antigen presentation mediated by Us3 kinase in infected cells was analyzed using a CTL hybridoma clone that produced β-galactosidase in response to the immunodominant gB_{498-505} epitope of HSV-1 [27]. As shown in Figure 4A, the response of the HSV-1-specific CTL hybridoma clone to B6MEFs infected with YK511 (Us3-K220M) was significantly greater than to B6MEFs infected with wild-type HSV-1(F) or YK513 (Us3-repair). This difference in the HSV-1-specific CTL hybridoma clone response was not observed in infected MHC-I-/-MEFs (Fig. 4B). In agreement with previous reports that ICP47 inhibits MHC-I antigen presentation poorly in mouse cells [11,12], the response of the HSV-1 specific CTL hybridoma clone to B6MEFs infected with the ICP47-null mutant virus YK591 (ΔICP47) was similar to the response of the clone to B6MEFs infected with wild-type HSV-1(F). These results indicated that Us3 kinase activity mediated the inhibition of MHC-I-restricted, HSV-1-specific antigen presentation in cultured infected cells.

Characterization of recombinant viruses YK511 (Us3K220M) and YK478 (UL41D213N) and their repaired viruses in MRC-5 and B6MEF cells

Ryckman and Roller previously reported that the kinase-dead mutation in Us3 impaired viral replication in HEp-2 cells but not in Vero cells [37]. To examine whether the kinase-dead mutation (K220M mutation in Us3) also impaired viral replication in MRC-5 and B6MEF cells, we analyzed viral growth of wild-type HSV-1(F), YK511 (Us3K220M) and YK513 (Us3K220M-repair) in MRC-5 and B6MEF cells infected at an MOI of 3 or 0.01. As shown in Figure S3, the progeny yield of YK511 (Us3K220M) in MRC-5 and B6MEF cells at both MOIs was reduced compared to wild-type HSV-1(F) and YK513 (Us3-repair) progeny virus yields.

To eliminate the possibility that the increase in MHC-I cell surface expression and MHC-I-restricted, HSV-1-specific antigen presentation in MRC-5 and B6MEF cells infected with YK511 (Us3K220M) resulted from the reduced growth of the mutant virus in these cells, we also characterized recombinant virus YK478 (UL41-D213N) carrying the D213N mutation in UL41 and its repaired virus YK479 (UL41-D213N-repair) in MRC-5 and B6MEF cells. The growth kinetics of YK478 (UL41D213N) in MRC-5 and B6MEF cells at MOIs of 3 and 0.01 was almost identical to that of YK511 (Us3K220M) (Fig. S3). The D213N mutation in UL41 has been reported to abolish vhs RNase activity in transfection experiments [38]. In agreement with this report, the level of cellular β-actin mRNA was significantly up-regulated in MRC-5 and B6MEF cells infected with YK478 (UL41-D213N) to a level similar to that in cells infected with the UL41 null mutant virus YK476 (ΔUL41), compared to the level of cellular β-actin mRNA in cells infected with wild-type HSV-1(F) and YK479 (UL41D213N-Repair) (Fig. S4), confirming that the D213N mutation in UL41 abolished vhs RNase activity in infected cells. Furthermore, we noted that the level of β-actin mRNA in MRC-5 and B6MEF cells infected with YK511 (Us3K220M) was similar to that in cells infected with wild-type HSV-1(F) (Fig. S4), indicating that the kinase-dead mutation in Us3 had no effect on vhs function in these infected cells.

We then examined total and cell surface expression of MHC-I and MHC-I-restricted, HSV-1-specific antigen presentation in
MRC-5 and B6MEF cells infected with wild-type HSV-1(F), YK478 (UL41-D213N) and YK479 (UL41D213N-repair). As shown in Figure S5A, MHC-I cell surface expression in MRC-5 cells infected with YK478 (UL41D213N) was similar to that of MRC-5 cells infected with wild-type HSV-1(F) or YK479 (UL41D213N-repair). In agreement with a previous report [38], the total accumulation of MHC-I protein was significantly increased in MRC-5 cells infected with YK478 (UL41D213N) compared to MRC-5 cells infected with wild-type HSV-1(F) or YK479 (UL41D213N-repair) (Fig. S5B). Similar results were also obtained for cell surface expression of H-2Kb and H-2Db in B6MEFs (Fig. S6). Furthermore, the response of an HSV-1 specific CTL hybridoma clone to B6MEFs infected with YK478 (UL41-D213N) was similar to the response of the clone to B6MEFs infected with wild-type HSV-1(F) or YK479 (UL41D213N-repair) (Fig. S7). Thus, inactivation of vhs RNase activity in infected MRC-5 and B6MEF cells decreased viral growth to a level almost identical to that produced by inactivation of Us3 kinase activity. However, unlike inactivation of Us3 kinase activity, inactivation of vhs RNase activity in MRC-5 and B6MEF cells had no effect on MHC-I cell surface expression or on inhibition of MHC-I-restricted, HSV-1-specific antigen presentation. These results indicated that both vhs and Us3 activities were required for efficient viral replication in MRC-5 and B6MEF cells, but vhs played no role in down-regulation of MHC-I cell surface expression in infected MRC-5 and B6MEF cells or in inhibition of MHC-I-restricted, HSV-1-specific antigen presentation in infected B6MEFs.

Effect of HSV-1 Us3 kinase activity on susceptibility of infected cells to NK cell recognition

MHC-I molecules are ligands for inhibitory receptors on NK cells [39]. Therefore, HSV-1 Us3-mediated inhibition of MHC-I cell surface expression in infected cells was proposed to increase recognition of cells infected with wild-type HSV-1 by NK cells more than cells infected with YK511 (Us3K220M). Consistent with this proposal, the amount of γ-interferon (γ-IFN), which is induced upon NK cell recognition of target cells [39], in the supernatants of IL-2 expanded NK cells co-cultured with B6MEFs infected with wild-type HSV-1(F) or YK513 (Us3-repair) was significantly greater than the amount of γ-IFN in the supernatants of IL-2 expanded NK cells co-cultured with B6MEFs infected with YK511 (Us3K220M) (Fig. 5A). In contrast, these differences in γ-IFN production were not observed with infected MHC-I-/-MEFs (Fig. 5B). These results indicated that Us3 kinase activity was required to make infected cells susceptible to NK-cell recognition and confirmed that Us3 kinase activity mediated down-regulation of cell surface expression of MHC-I in infected cells.

Effect of HSV-1 Us3 kinase activity on HSV-1-specific CTL induction in vivo.

To investigate the role of HSV-1 Us3 kinase activity in HSV-1-specific CTL induction in vivo, CD8+ T cells specific for the immunodominant gB_498-505 epitope of HSV-1 [40] were measured in mice infected in a hind footpad with wild-type HSV-1(F), YK511 (Us3K220M), YK513 (Us3-repair) or YK591 (ΔICP47). As shown in Figure 6, YK511 (Us3K220M) elicited significantly more HSV-1-specific CTLs both in spleens and popliteal lymph nodes of mice than wild-type HSV-1(F), YK511 (Us3-K220M), or YK513 (Us3-Repair) at an MOI of 1 for 12 h and then co-cultured with NK cells isolated from C57BL/6J mouse splenocytes for an additional 24 h. IFN-γ in the co-culture cell supernatants was quantified by ELISA. Each data point is the mean ± standard error of triplicate samples, and is representative of three independent experiments.

doi: 10.1371/journal.pone.0072050.g005

Figure 5. Effect of Us3 kinase activity on susceptibility of HSV-1-infected cells to NK cell recognition. B6MEFs (A) and MHC-I-/-MEFs (B) were infected with HSV-1-(F), YK511 (Us3-K220M), or YK513 (Us3-Repair) at an MOI of 1 for 12 h and then co-cultured with NK cells isolated from C57BL/6J mouse splenocytes for an additional 24 h. IFN-γ in the co-culture cell supernatants was quantified by ELISA. Each data point is the mean ± standard error of triplicate samples, and is representative of three independent experiments.

Effect of depletion of CD8+ T or NK cells in mice on replication of the Us3 kinase-dead mutant virus

As described above, Us3 kinase activity in infected cells appeared to have opposite effects on HSV-1-specific CTLs and NK cells co-cultured with infected cells with regard to elimination of the infected cells by immune system cells. Therefore, we examined which aspect of in vitro Us3 kinase activity was critical for viral replication in vivo. For this study, the hind footpads of mice were inoculated with YK511 (Us3K220M) or YK513 (Us3-repair) or YK591 (ΔICP47). These results indicated that Us3 kinase activity down-regulated HSV-1-specific CD8+ CTL induction in vivo.

Effect of depletion of CD8+ T or NK cells in mice on replication of the Us3 kinase-dead mutant virus

As described above, Us3 kinase activity in infected cells appeared to have opposite effects on HSV-1-specific CTLs and NK cells co-cultured with infected cells with regard to elimination of the infected cells by immune system cells. Therefore, we examined which aspect of in vitro Us3 kinase activity was critical for viral replication in vivo. For this study, the hind footpads of mice were inoculated with YK511 (Us3K220M) or YK513 (Us3-repair) or YK591 (ΔICP47). These results indicated that Us3 kinase activity down-regulated HSV-1-specific CD8+ CTL induction in vivo.
However, at 4 d post-infection, when YK511 (Us3K220M) had induced more HSV-1-specific CTLs than YK513 (Us3-repair), as described above (Fig. 6), depletion of CD8+ T cells significantly (6-fold) increased replication of YK511 (Us3K220M) in the footpads, but had no effect on replication of YK513 (Us3-repair) (Fig. 7A). These results suggested that Us3-mediated evasion of CD8+ T cells might in part contribute to efficient viral replication in vivo.

Discussion

Detailed studies of the molecular mechanisms by which alphaherpesvirus proteins act on the steps of the MHC-I antigen presentation pathway in vitro that have been reported to date [2] contrast with the lack of data on the in vivo functions of these proteins. In alphaherpesviruses, only HSV protein ICP47 has been reported to be involved in CD8+ T cell evasion in mice in vivo, as described above [14]. However, the reported effect of ICP47 on the MHC-I presentation pathway in vitro [8] is not the same in mouse cells [11,12], as we confirmed both in vitro and in vivo in this study. Therefore, the mechanism by which ICP47 functions in CD8+ T cell evasion in mice was unclear and indicated that a mechanism(s) other than inhibition of the MHC-I presentation pathway may be involved. We have shown here that inactivation of HSV-1 Us3 kinase activity significantly increased cell surface expression of MHC-I and HSV-1-specific antigen presentation in infected cells. These results were in agreement with the agonistic effect of the increased MHC-I cell surface expression on NK cell repression observed in this study. We also showed that inactivation of HSV-1 Us3 kinase activity induced significantly more HSV-1-specific CTLs in infected mice and that CD8+ T cell depletion significantly increased replication of the Us3 kinase-dead mutant virus in mice, although it had no effect on replication of the virus in which the Us3 mutation was repaired. Taken together, these experimental results indicated that Us3 kinase activity was required for efficient downregulation of cell surface expression of MHC-I and mediated evasion of HSV-1-specific CD8+ T cells and raised the possibility that this immune evasion might in part contribute to efficient viral replication in vivo. We note that the effect of Us3 on downregulation of MHC-I appeared to be indirect, based on the observations that overexpression of Us3 had no effect on cell surface expression of MHC-I and Us3 was not able to phosphorylate MHC-I in an in vitro kinase assay.

It has been reported that HSV-infected cells can inactivate CTL function and that Us3 is required for the CTL inactivation [42]. Based on this study, the increased activity of the HSV-1-specific CTL hybridoma clone against cells infected with the Us3 kinase-dead mutant virus compared to wild-type virus may not have been due to Us3-mediated inhibition of MHC-I cell.
Six 6-week-old female C57BL/6J mice were mock-depleted or depleted of CD8+ T cells in vivo. These results suggested that the reduction in YK511 (Us3K220M) replication in the footpads of mice at 4 d post-infection was not solely due to rapid loss of YK511 (Us3K220M) by CTLs. It has been reported that Us3 is a multifunctional viral protein kinase regulating a variety of cellular and viral activities in infected cells, including (i) blocking apoptosis [43–46], (ii) promoting nuclear egress of progeny nucleocapsids through the nuclear membrane (NM) [37,47,48], (iii) redistributing and phosphorylating NM-associated viral nuclear egress factors UL31 and UL34 and cellular factors lamin A/C and emerin [32,49–53], (iv) mediating phosphorylation of histone deacetylases (HDACs) and promoting gene expression by blocking histone deacetylation [54], (v) controlling infected cell morphology [29,45], (vi) down-regulating cell surface expression of viral envelope protein gB by promoting endocytosis of gB [30,31], (vii) stimulating mRNA translation by mimicking Akt and activating mTORC1 [55] and (viii) modulating host immune systems [20–22,56–58]. The effect in YK511 (Us3K220M) replication in the footpads of mice may have also been caused by inactivation of some of the Us3 functions that have been reported to promote viral replication in vivo [59,60].

Although we showed here that Us3 kinase activity resulted in NK cell recognition of infected cells in vitro, NK cell depletion had no effect on replication of wild-type or Us3 kinase-dead virus at the site of infection in mice following footpad inoculation. These observations were in agreement with a previous report [61] showing that NK cells do not significantly contribute to control of HSV-1 replication at the site of infection in mice following footpad inoculation. However, it has been reported that the effects of NK cells on HSV infection in mice are dependent on the route of viral inoculation, and NK cell depletion in mice following ocular, intraperitoneal and intravascular inoculation increased the susceptibility of mice to HSV infection [62]. Therefore, it would be interesting to compare the effects of depletion of NK and CD8+ T cells on HSV infection in mice inoculated by these routes.

Information on the mechanism(s) by which HSV evades the host cell immune response is important both for understanding viral strategies for survival in their hosts and for developing effective vaccines against HSV, which has not been clinically successful to date [1]. It has been reported that UL41 is involved in inhibition of maturation of dendritic cells, key cells in stimulating and directing the development of adaptive immune responses [63], and that disruption of UL41 increases the immunogenicity and protective capacity of a potential, replication-incompetent HSV vaccine [64]. The present study, showing that inactivation of Us3 kinase activity increased HSV-1-specific CTL induction in mice, suggested that disruption of Us3 may be another method for increasing the immunogenicity and protective capacity of potential HSV vaccines. Furthermore, it has been reported that Us3 mutant viruses exhibited markedly reduced virulence and capacity for latent infection in mice [59,60]. These observations raised the possibility that HSV-1 Us3 mutant viruses could be potential candidates for novel, safe, live-attenuated, vaccine platforms against HSV-1 infection.
Supporting Information

Figure S1. Verification of CD8+ (A and C) and NK1.1+ (B and D) cell depletion in C57BL/6J mice. Six-week-old C57BL/6J mice were injected intraperitoneally with PBS, or 200 µg anti-CD8α or NK1.1 antibody. Cells from spleen and popliteal lymph nodes were stained with anti-CD8α or anti-NK 1.1 antibody and analyzed by flow cytometry 2 d after antibody administration. The results of first (A and B) and second (C and D) experiment are shown as log-log dot plots. (TIF)

Figure S2. (A) Effect of Us3 expression on cell surface expression of MHC-I in 293T cells. 293T cells were co-transfected with 1.6 µg of pEGFP-C1 in combination of 1.6 µg pFLAG-Us3 or pFLAG-CMV2. At 48 h after transfection, cell surface expression of MHC-I in transfected cells were analyzed by flow cytometry. (B) Us3 does not directly phosphorylate MHC-I in vitro. Purified MBP-gB (lane 1), MBP-gB-T887A (lane 2), MBP-MHC-I-SS336/337AA (lanes 3 and 5) and MBP-MHC-I-32P (lanes 4 and 6) were incubated in kinase buffer containing [γ-32P] ATP and purified GST-Us3 (lanes 1 to 4) or protein kinase A (PKA) (lanes 5 and 6), separated on a denaturing gel, and stained with CBB (upper panel). An autoradiograph of the gel in upper panel is shown in the lower panel. (TIF)

Figure S3. Effect of Us3 kinase activity and vhs enzymatic activity on viral growth in MRC-5 and B6MEFs cells. MRC-5 (A and B) and B6MEFs cells (C and D) were infected at an MOI of 3 (A and C) or 0.01 (B and D) with each of the indicated wild-type and recombinant viruses. Total virus from the cell culture supernatants and the infected cells was harvested at the indicated times and assayed on Vero cells. (TIF)

Figure S4. Effect of Us3 kinase activity and vhs enzymatic activity on expression of β-actin mRNA in infected cells. MRC-5 (A and B) and B6MEFs cells (B) were mock-infected or infected with each of the indicated wild-type and recombinant viruses at an MOI of 3, harvested at 18 h post-infection and the amount of β-actin mRNA was analyzed by quantitative RT-PCR. Each bar is the mean ± standard error of data from three independent experiments. The mean value for each of the indicated viruses was calculated relative to that for the corresponding mock-infected cells, which was normalized to 100. (TIF)

Figure S5. Effect of vhs enzymatic activity on cell surface and total expression of MHC-I in HSV-1-infected MRC-5 cells. (A) Surface expression of MHC-I in MRC-5 cells infected with HSV-1(F), YK511 (Us3-K220M), YK478 (UL41D213N) or YK479 (UL41D213N-repair) at an MOI of 3 for 18 h and analyzed and quantitated as described in (Figure 2B). Each data point is the mean ± standard error of triplicate samples, and is representative of three independent experiments. (B) Total accumulation of MHC-I in MRC-5 cells mock-infected or infected with HSV-1(F), YK511 (Us3-K220M), YK478 (UL41D213N) or YK479 (UL41D213N-repair) at an MOI of 3 for 18 h and analyzed and quantitated as described in (Figure 2B). The data were calculated relative to mock-infected cells, which was normalized to 100. Each data point is the mean ± standard error of triplicate samples, and is representative of three independent experiments. (TIF)

Figure S6. Effect of vhs enzymatic activity on cell surface and total expression of MHC-I (H-2Kb and H-2Db) in HSV-1-infected B6MEFs. (A and C) Surface expression of H-2Kb (A) and H-2Db (C) in B6MEFs infected with HSV-1(F), YK511 (Us3-K220M), YK478 (UL41D213N) or YK479 (UL41D213N-repair) at an MOI of 3 for 18 h and analyzed and quantitated as described in (Figure 2B). Each data point is the mean ± standard error of triplicate samples, and is representative of three independent experiments. The data were calculated relative to mock-infected cells, which was normalized to 100. (B and D) Total accumulation of H-2Kb (B) and H-2Db (D) in B6MEFs mock-infected or infected with HSV-1(F), YK511 (Us3-K220M), YK478 (UL41D213N) or YK479 (UL41D213N-repair) at an MOI of 3 for 18 h and analyzed and quantitated as described in (Figure 2B). The data were calculated relative to mock-infected cells, which was normalized to 100. Each data point is the mean ± standard error of triplicate samples, and is representative of three independent experiments. (TIF)

Figure S7. Effect of vhs enzymatic activity on HSV-1-specific antigen presentation. B6MEFs were infected with wild-type HSV-1(F), YK511 (Us3-K220M), YK478 (UL41-D213N) or YK479 (UL41-D213N-repair) at an MOI of 1 for 12 h and then co-cultured for an additional 12 h with lacZ-inducible CTL hybridoma cells recognizing HSV-1 gB (HSV-2.3.2E2), followed by β-galactosidase assays. Each data point is the mean ± standard error of triplicate samples, and is representative of three independent experiments. (TIF)

Acknowledgements

We thank A.B. Hill and F.R. Carbone for providing MHC-I−/− MEFs and HSV-2.3.2E2 cells, respectively. We thank Shihoko Koyama and Tomoko Ando for excellent technical assistance.

Author Contributions

Conceived and designed the experiments: TI YK. Performed the experiments: TI NK RO KS. Analyzed the data: TI TS AS JA AK HK HA YK. Contributed reagents/materials/analysis tools: TS AS JA AK HK HA. Wrote the manuscript: TI YK.
References

1. Roizman B, Kneip DM, Whitley RJ (2007) Herpes Simplex Viruses. In: DM Kneip, PM Howley, DE Griffin, LM Martin, F Fields Virology. 5th ed. Philadelphia, PA: Lippincott-Williams & Wilkins.

2. Hansen TH, Bouvier M (2009) MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol 9: 503-513. doi: 10.1038/nri.2009.55. PubMed: 19458380.

3. Horst D, Verweij MC, Davison AJ, Ressing ME, Wiertz EJ (2011) Viral evasion of T cell immunity: ancient mechanisms offering new applications. Curr Opin Immunol 23: 96-103. doi:10.1016/j.coi.2010.11.005. PubMed: 21163836.

4. Neefjes J, Jongsma ML, Paul P, Bakke O (2011) Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 11: 823-836. PubMed: 22076556.

5. Stevenson PG, May JS, Smith XG, Marques S, Adler H et al. (2002) Herpesvirus directs human HLA-A,-B,-C T cell antigen presentation and HLA class I expression by varicella-zoster virus. Nature 413: 733-740. doi:10.1038/nrg8922. PubMed: 12101398.

6. Krmpotíc A, Messerle M, Cmokovic-Mertens I, Pobi B, Jonjic S et al. (1994) A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T cells: critical for superinfection by cytomegalovirus. Science 328: 102-106. doi:10.1126/science.7815530. PubMed: 20360110.

7. Hansen SG, Towns CJ, Richards R, Ventura AB, Ford JC et al. (2010) Evasion of CDB+ T cells is critical for superinfection by cytomegalovirus. PLoS Pathog 6: 1-15. doi:10.1371/journal.ppat.1000746. PubMed: 20447478.

8. Hill AJ, Uema M, Morimoto T, Sagara H, Akashi H et al. (2009) Entry of herpes simplex virus 1 and other alphaherpesviruses via the paired immunoglobulin-like type 2 receptor alpha. J Virol 83: 4520-4527. doi:10.1128/JVI.02601-08. PubMed: 19244335.

9. Mueller SN, Jones CM, Smith CM, Heath WR, Carbone FR (2002) Rapid cytoxix T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus. J Virol 76: 651-656. doi:10.1128/JVI.01220-02. PubMed: 11877488.

10. Kato A, Ito T, Satoh I, Iida T, Sagara K et al. (2012) Herpes simplex virus 1 VP22 regulates transduction of multiple viral and cellular proteins and promotes neurovirulence. J Virol 86: 5246-5277. doi:10.1128/JVI.00913-11. PubMed: 22357273.

11. Kato A, Tanaka M, Yamamoto M, Asai R, Sata T et al. (2008) Identification of a physiologically phosphorylated site of the herpes simplex virus 1-encoded protein kinase Us3 which regulates its optimal catalytic activity in vitro and influences its function in infected cells. J Virol 82: 6172-6189. doi:10.1128/JVI.00444-08. PubMed: 18417577.

12. Imai T, Arii J, Minowa A, Koyanagi Y, Iida T et al. (2011) Identification of the herpes simplex virus 1 US3 kinase phosphorylation site and endocytosis motifs in the intracellular transport and neurovirulence of envelope glycoprotein B. J Virol 85: 5003-5015. doi:10.1128/JVI.05865-10. PubMed: 21163110.

13. Roizman B, Knipe DM, Whitley RJ (2007) Herpes Simplex Viruses. In: DM Knipe, PM Howley, DE Griffin, RA Lamb, MA Martin, JD Farber, ed. Philadelphia, P.A.: Lippincott-Williams & Wilkins.

14. Jarosinski KW, Hunt HD, Osterrieder N (2010) Down-regulation of MHC class I family sequence motifs in herpesvirus infection: a viral strategy to escape the immune system. Virology 405: 457-463. doi:10.1016/j.virol.2009.09.019. PubMed: 19819514.

15. Rao P, Pham HT, Kulkarni A, Yang Y, Liu X et al. (2011) Herpes simplex virus 1 glycoprotein B and US3 collaborate to inhibit CD1d antigen presentation and VIOLINK. J Virol 85: 8503-8514. doi:10.1128/JVI.02689-10. PubMed: 21653669.

16. Ma G, Feinesi S, Osterrieder N, Van de Walle GR (2012) Identification and characterization of equine herpesvirus type 1 UL56 and its role in virus-induced downregulation of major histocompatibility complex class I. J Virol 86: 3577-3583. doi:10.1128/JVI.00989-11. PubMed: 22278226.

17. Said A, Azab W, Damiani A, Osterrieder N (2012) Equine herpesvirus type 4 UL56 and UL49.5 proteins downregulate cell surface major histocompatibility complex class I. J Virol 86: 8059-8071. doi:10.1128/JVI.00891-12. PubMed: 22623773.

18. Arii J, Goto H, Suenaga T, Oyama M, Kozuka-Hata H et al. (2010) Non-muscle myosin IIA is a functional entry receptor for herpes simplex virus-1. Nature 467: 859-862. doi:10.1038/nature09420. PubMed: 20944748.

19. Hill AJ, Ueda M, Morimoto T, Sagara H, Akashi H et al. (2009) Entry of herpes simplex virus 1 and other alphaherpesviruses via the paired immunoglobulin-like type 2 receptor alpha. J Virol 83: 4520-4527. doi:10.1128/JVI.02601-08. PubMed: 19244335.

20. Mueller SN, Jones CM, Smith CM, Heath WR, Carbone FR (2002) Rapid cytoxix T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus. J Virol 76: 651-656. doi:10.1128/JVI.01220-02. PubMed: 11877488.
38.  Everly DN Jr., Peng P, Mian IS, Read GS (2002) mRNA degradation by the virion host shutoff (Vhs) protein of herpes simplex virus: genetic and biochemical evidence that Vhs is a nuclease. J Virol 76: 8560-8571. doi:10.1128/JVI.76.17.8560-8571.2002. PubMed: 12163576.

39.  Lodden MB, Lanier LL (2005) Viral modulation of NK cell immunity. Nat Rev Microbiol 3: 59-69. doi:10.1038/nmicro1066. PubMed: 15668700.

40.  Hanke T, Graham FL, Rosenthal KL, Johnson DC (1991) Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides. J Virol 65: 1177-1186. PubMed: 1847447.

41.  Coles RM, Mueller SN, Heath WR, Carbone FR, Brooks AG (2002) Progression of armed CTL from draining lymph node to spleen shortly after localized infection with herpes simplex virus 1. J Immunol 168: 834-838. PubMed: 11777979.

42.  Sloan DD, Zahariadis G, Posavac CM, Pate NT, Kussick SJ et al. (2003) CTL are inactivated by herpes simplex virus-infected cells expressing a viral protein kinase. J Immunol 171: 6733-6741. PubMed: 1462877.

43.  Leopardi R, Van Sant C, Roizman B (1997) The herpes simplex virus 1 protein kinase US3 is required for protection from apoptosis induced by the virus. Proc Natl Acad Sci U S A 94: 7891-7896. doi:10.1073/pnas.94.15.7891. PubMed: 9223283.

44.  Munger J, Chee AV, Roizman B (2001) The U(S)3 protein kinase blocks apoptosis induced by the d120 mutant of herpes simplex virus 1 at a premitochondrial stage. J Virol 75: 5491-5497. doi:10.1128/JVI.75.12.5491-5497.2001. PubMed: 11356956.

45.  Munger J, Roizman B (2001) The US3 protein kinase of herpes simplex virus 1 mediates the posttranslational modification of BAD and prevents Bcl-2-induced programmed cell death in the absence of other viral proteins. Proc Natl Acad Sci U S A 98: 10410-10415. doi:10.1073/pnas.151024198. PubMed: 11517326.

46.  Ogg PD, McDonell PJ, Ryckman BJ, Knudson CM, Roller RJ (2004) US3 protein kinase is sufficient to block apoptosis induced by overexpression of a variety of Bcl-2 family members. Virology 319: 212-224. doi:10.1016/j.virol.2003.10.019. PubMed: 14980482.

47.  Mou F, Wills E, Baines JD (2009) Phosphorylation of the U(L)31 protein by overexpression of a variety of Bcl-2 family members. Virology 319: 251-254. doi:10.1016/0042-6822(88)90417-5. PubMed: 2827384.

48.  Poon AP, Gu H, Roizman B (2006) ICP0 and the US3 protein kinase of herpes simplex virus-1 independently block histone deacetylation to enable gene expression. J Virol 80: 6459-6470. doi:10.1128/JVI.00380-07. PubMed: 17301149.

49.  Poon AP, Gu H, Roizman B (2006) ICP0 and the US3 protein kinase of herpes simplex virus type 1 encodes a promiscuous protein kinase that phosphorylates and alters localization of lamin A/C in infected cells. J Virol 81: 4429-4437. doi:10.1128/JVI.02354-06. PubMed: 17031149.

50.  Morris JB, Hofemeister H, O'Hare P (2007) Herpes simplex virus infection induces phosphorylation and delocalization of emerin, a key inner nuclear membrane protein. J Virol 81: 4429-4437. doi:10.1128/JVI.02354-06. PubMed: 17031149.

51.  Sajgo K, Rajasagi NK, Ritz BW, Pruitt SB, Gardner EM et al. (2009) Dendritic cells are required for optimal activation of natural killer functions following primary infection with herpes simplex virus type 1. J Virol 83: 5763-5763. doi:10.1128/JVI.00150-09. PubMed: 19297494.

52.  Meignier B, Longnecker R, Mavromara-Nazos P, Sears AE, Roizman B (1988) Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1. Virology 162: 1320-1322. doi:10.1016/0042-6822(88)90417-5. PubMed: 2827384.

53.  Sagou K, Rajasagi NK, Ritz BW, Pruitt SB, Gardner EM et al. (2009) Dendritic cells are required for optimal activation of natural killer functions following primary infection with herpes simplex virus type 1. J Virol 83: 3175-3186. doi:10.1128/JVI.01907-08. PubMed: 19144708.

54.  Cartier A, Broberg E, Komal T, Henriksson M, Masucci MG (2003) The herpes simplex virus-1 Us3 protein kinase blocks CDB7 cell lysis by preventing the cleavage of Bid by granzyme B. Cell Death Differ 10: 1213-1218. doi:10.1038/sj.cdd.4401308. PubMed: 12634063.

55.  Cartier A, Masucci MG (2004) Differential regulation of MHC class-I-restricted and unrestricted cytotoxicity by the US3 protein kinase of herpes simplex virus. Scand J Immunol 60: 592-599. doi:10.1111/j.1365-3030.2003.01523.x. PubMed: 15584970.

56.  Sen J, Liu X, Roller R, Knipe DM (2013) Herpes simplex virus US3 tegument protein inhibits Toll-like receptor 2 signaling at or before TRAF6 ubiquitination. Virology 439: 65-73. doi:10.1016/j.virol.2013.01.026. PubMed: 2378027.

57.  Purves FC, Spector D, Roizman B (1991) The herpes simplex virus 1 protein kinase encoded by the US3 gene mediates posttranslational modification of the phosphoprotein encoded by the UL34 gene. J Virol 65: 5767-5774. PubMed: 1856069.

58.  Reynolds AE, Ryckman BJ, Baines JD, Zhou Y, Liang L et al. (2001) UL(L)31 and UL(L)34 proteins of herpes simplex virus type 1 form a complex that accumulates at the nuclear rim and is required for envelopment of nucleocapsids. J Virol 75: 8803-8817. doi:10.1128/JVI.75.18.8803-8817.2001. PubMed: 11507225.

59.  Griffiths JH, Rahmsdorff O, Coulthard LE, Curran H, McLean J et al. (2001) The U(S)L34 glycoprotein of herpes simplex virus type 1 is a transmembrane receptor required for cell entry and entry into latency. J Gen Virol 82: 741-752. doi:10.1099/0022-1317-82-3-741. PubMed: 11225749.

60.  Kassim SH, Rajasagi NK, Ritz BW, Pruett SB, Gardner EM et al. (2009) Dendritic cells are required for optimal activation of natural killer functions following primary infection with herpes simplex virus type 1. J Virol 83: 3175-3186. doi:10.1128/JVI.01907-08. PubMed: 19144708.

61.  Chew T, Taylor KE, Moxman KL (2009) Innate and adaptive immune responses to herpes simplex virus. Viruses 1: 979-1002. doi:10.3390/v1030979. PubMed: 21994578.

62.  Samady L, Costiglioni E, MacCormac L, McGrath Y, Cleverley S et al. (2003) Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy. J Virol 77: 3768-3776. doi:10.1128/JVI.77.6.3768-3776.2003. PubMed: 12610151.

63.  Dudek T, Mathews LC, Knipe DM (2008) Disruption of the UL(U)L41 gene in the herpes simplex virus 2 dil5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 372: 165-175. doi:10.1016/j.virol.2007.10.014. PubMed: 18060633.